Not if you can't say that your mouse trap catches mice and you can't say why that is good. Tamper resistant opioid are different. The FDA is allowing them to say things in the label. With regards to pseudo, both the DEA and FDA will weigh in and the DEA will protest any language that states anything about how much "better" the product is at stopping meth production.
And just think how law enforcement could be aided by the lists provided (which are already in place and are being strengthed by reducing millagram amount of pseudoephedrine that can be purchased monthly) on who and how much product is moving. So much for freedom, and we already know cameras are everywhere. Oh Well!
If I were Acura I would partner with store branded pseudoephedrine products. Of course this would hurt the margins on Nexafed TM, but sales would come in a hurry. Meth producers shop for a living, and their choice is going to be the product or products without the Impede TM technology.
Doesn't it ultimately boil down to who has the better mouse trap? The technology will never be perfect, just one step closer. Kind of like a filter on the end of a cigarette.
Thanks for your insight.
Hence the problem. There is no benefit granted by the government and no benefit granted by the technology as there are always a work around to it and they will not be able to accurately track when there product is being used to make meth. So they intend to have a manufacturer buy there product why? There is no benefit and this is a wasted use of their capital.
On the presentation today- Bob Jones says Nexafed allows 1/2 the meth to be produced and some of their patents on Impede are pending, not granted. UGH
He also said that it would be behind the counter more than likely. So where is the benefit?
He said they do not know what they DEA standard is to make it OTC or the tests- WTH
GCE owns 35 Million shares of the float ~ 75%
I think PFE is very interested in the tamper resistant field as they know it will be the required standard. It has already been documented that the new OxyContin is resulting in lower abuse rates in certain areas and that product is using a mediocre technology.